Effect of Osteopathic Manipulative Treatment vs Sham Treatment on Activity Limitations in Patients With Nonspecific Subacute and Chronic Low Back Pain: A Randomized Clinical Trial

Christelle Nguyen, Isabelle Boutron, Rafael Zegarra-Parodi, Gabriel Baron, Sophie Alami, Katherine Sanchez, Camille Daste, Margaux Boisson, Laurent Fabre, Peggy Krief, Guillaume Krief, Marie-Martine Lefèvre-Colau, François Rannou, Christelle Nguyen, Isabelle Boutron, Rafael Zegarra-Parodi, Gabriel Baron, Sophie Alami, Katherine Sanchez, Camille Daste, Margaux Boisson, Laurent Fabre, Peggy Krief, Guillaume Krief, Marie-Martine Lefèvre-Colau, François Rannou

Abstract

Importance: Osteopathic manipulative treatment (OMT) is frequently offered to people with nonspecific low back pain (LBP) but never compared with sham OMT for reducing LBP-specific activity limitations.

Objective: To compare the efficacy of standard OMT vs sham OMT for reducing LBP-specific activity limitations at 3 months in persons with nonspecific subacute or chronic LBP.

Design, setting, and participants: This prospective, parallel-group, single-blind, single-center, sham-controlled randomized clinical trial recruited participants with nonspecific subacute or chronic LBP from a tertiary care center in France starting February 17, 2014, with follow-up completed on October 23, 2017. Participants were randomly allocated to interventions in a 1:1 ratio. Data were analyzed from March 22, 2018, to December 5, 2018.

Interventions: Six sessions (1 every 2 weeks) of standard OMT or sham OMT delivered by nonphysician, nonphysiotherapist osteopathic practitioners.

Main outcomes and measures: The primary end point was mean reduction in LBP-specific activity limitations at 3 months as measured by the self-administered Quebec Back Pain Disability Index (score range, 0-100). Secondary outcomes were mean reduction in LBP-specific activity limitations; mean changes in pain and health-related quality of life; number and duration of sick leaves, as well as number of LBP episodes at 12 months; and consumption of analgesics and nonsteroidal anti-inflammatory drugs at 3 and 12 months. Adverse events were self-reported at 3, 6, and 12 months.

Results: Overall, 200 participants were randomly allocated to standard OMT and 200 to sham OMT, with 197 analyzed in each group; the median (range) age at inclusion was 49.8 (40.7-55.8) years, 235 of 394 (59.6%) participants were women, and 359 of 393 (91.3%) were currently working. The mean (SD) duration of the current LBP episode was 7.5 (14.2) months. Overall, 164 (83.2%) patients in the standard OMT group and 159 (80.7%) patients in the sham OMT group had the primary outcome data available at 3 months. The mean (SD) Quebec Back Pain Disability Index scores for the standard OMT group were 31.5 (14.1) at baseline and 25.3 (15.3) at 3 months, and in the sham OMT group were 27.2 (14.8) at baseline and 26.1 (15.1) at 3 months. The mean reduction in LBP-specific activity limitations at 3 months was -4.7 (95% CI, -6.6 to -2.8) and -1.3 (95% CI, -3.3 to 0.6) for the standard OMT and sham OMT groups, respectively (mean difference, -3.4; 95% CI, -6.0 to -0.7; P = .01). At 12 months, the mean difference in mean reduction in LBP-specific activity limitations was -4.3 (95% CI, -7.6 to -1.0; P = .01), and at 3 and 12 months, the mean difference in mean reduction in pain was -1.0 (95% CI, -5.5 to 3.5; P = .66) and -2.0 (95% CI, -7.2 to 3.3; P = .47), respectively. There were no statistically significant differences in other secondary outcomes. Four and 8 serious adverse events were self-reported in the standard OMT and sham OMT groups, respectively, though none was considered related to OMT.

Conclusions and relevance: In this randomized clinical trial of patients with nonspecific subacute or chronic LBP, standard OMT had a small effect on LBP-specific activity limitations vs sham OMT. However, the clinical relevance of this effect is questionable.

Trial registration: ClinicalTrials.gov Identifier: NCT02034864.

Conflict of interest statement

Conflict of Interest Disclosures: Prof Boutron reported receiving grants from the French Ministry of Health during the conduct of the study. Mr Zegarra-Parodi reported practicing as a registered osteopath in France and providing undergraduate and postgraduate courses in osteopathy. Dr Alami worked for Interlis and was hired by Assistance Publique-Hôpitaux de Paris to provide an assessment of the speech of the osteopathic practitioners. Mr Fabre reported practicing as a registered osteopath in France. Mr G. Krief reported practicing as a registered osteopath in Switzerland and providing postgraduate courses in osteopathy at the HES-SO-Fribourg. Prof Rannou reported receiving academic grants from Assistance Publique-Hôpitaux de Paris during the conduct of the study as well as grants from H2020 and Programme Hospitalier de Recherche Clinique outside the submitted work. No other disclosures were reported.

Figures

Figure 1.. CONSORT Diagram
Figure 1.. CONSORT Diagram
OMT indicates osteopathic manipulative treatment. aAccording to French regulation, no data were analyzed for these patients. bThis patient did not receive allocated intervention.
Figure 2.. Cumulative Percentage of Responders’ Analysis…
Figure 2.. Cumulative Percentage of Responders’ Analysis With Change in Quebec Back Pain Disability Index (QBPDI) Score at 3 Months
At 3 months, data were available for 164 participants in the standard osteopathic manipulative treatment (OMT) group and 159 in the sham OMT group.
Figure 3.. Summary of Speech Content and…
Figure 3.. Summary of Speech Content and Verbal Attitude of Osteopathic Practitioners According to Standard or Sham Osteopathic Manipulative Treatment (OMT)
Scores range from 0 (not at all) to 2 (high).

Source: PubMed

3
Sottoscrivi